OAS Logo

Log in

Recent Posts from the OASIS Newsletter

OASIS Newsletter Fall 2024

30 Oct 2024 5:52 PM | Rachael Reed (Administrator)
Greetings OAS Members,

2024 has been a year of excitement. We held a very successful Scientific Conference in Houston. Next year we are hosting the 38th Annual OAS Scientific Meeting in Dallas, Texas, February 21-23.  Registration will open next week, but mark your calendar now. The meeting will again feature the optional orbital block workshop on Sunday, limited to 20. 

It isn't too early to make your hotel reservation at the Adolphus Hotel in downtown Dallas. Take a peek at the draft agenda here

We will see you in Dallas! 

Two Quick Surveys

The OAS board is interested in your experience with vitreoretinal  surgery (VR). 
Please take this 6 question survey

And if you have not done so already, complete this brief survey regarding future OAS meetings. You can volunteer yourself as a speaker!

In The News

OAS board member Vinodkumar Singh, MD of the Birmingham VA Medical Center in Alabama shares "Semaglutide: There’s More to It Than Meets the Eye!" He explains that patients using these medications may be at a higher risk for a serious eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION).

Did you know that an ophthalmologist currently serving in Congress is up for reelection? Mariannette Miller-Meeks, MD, was first elected in 2020 and is running for reelection in Iowa’s 1st District. She has been a strong advocate for ophthalmology as a lead sponsor of legislation to improve step therapy  protocols and strengthen patient protections. She also championed the push to improve Medicare’s 2022 payment rates for combined glaucoma-cataract surgery as well as efforts to prevent steep cuts to Medicare and to reduce prior authorization burdens. Learn more about Dr. Miller-Meeks at https://millermeeks.house.gov

Feds Still Urge Conservation Amid IV Fluid Shortage. The U.S. Department of Health and Human Services noted in an October 9 letter to health care leaders that it is addressing supply chain disruptions, and its update two days later noted that FDA is temporarily importing IV products from five international sources as well as encouraging production ramp-ups from U.S. facilities. The agency has also issued a list of conservation strategies for hospitals and health care professionals.



Copyright © 2023 Ophthalmic Anesthesia Society. All Rights Reserved.

Powered by Wild Apricot Membership Software